American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. - Suppr | 超能文献

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

作者信息

Walsh Patrick C

出版信息

J Urol. 2005 Jun;173(6):1966. doi: 10.1097/01.ju.0000161196.52248.3e.

DOI:10.1097/01.ju.0000161196.52248.3e

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

J Urol. 2005 Jun;173(6):1966. doi: 10.1097/01.ju.0000161196.52248.3e.

2

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.前列腺癌患者中，草药补充剂PC-SPES与己烯雌酚用于雄激素非依赖性前列腺癌的前瞻性、多中心、随机II期试验。

J Clin Oncol. 2004 Sep 15;22(18):3705-12. doi: 10.1200/JCO.2004.10.195. Epub 2004 Aug 2.

3

[Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].[完全激素阻断与单纯激素阻断治疗前列腺癌的比较]

Arch Esp Urol. 2002 Sep;55(7):771-5.

4

[PSA progression under hormone therapy - of prognostic relevance?].[激素治疗下前列腺特异性抗原进展——具有预后相关性？]

Aktuelle Urol. 2012 Jul;43(4):262-4. doi: 10.1055/s-0032-1321735. Epub 2012 Aug 6.

5

PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.PC-SPES：一种用于治疗激素难治性前列腺癌的草药疗法。

Prostate Cancer Prostatic Dis. 2002;5(1):13-5. doi: 10.1038/sj.pcan.4500563.

6

Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.研究改变了医生治疗转移性前列腺癌的方式：作者称，间歇性激素疗法不如持续性激素疗法有效。

Cancer. 2013 Sep 1;119(17):3103-4. doi: 10.1002/cncr.28314.

7

The clinical and biological study of androgen independent prostate cancer (AI PCa).雄激素非依赖性前列腺癌（AI PCa）的临床与生物学研究。

Semin Oncol. 1994 Oct;21(5):620-9.

8

Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.己烯雌酚与多西他赛：转移性雄激素非依赖性前列腺癌患者中微管活性剂的II期研究。

Cancer. 2007 Sep 1;110(5):996-1002. doi: 10.1002/cncr.22917.

9

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.雄激素剥夺疗法（ADT）在晚期前列腺癌患者中的疗效： Gleason评分、前列腺特异性抗原水平以及既往ADT暴露与ADT疗效持续时间之间的关联。

Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304.

10

Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.激素难治性前列腺癌患者停用磷酸雌莫司汀后前列腺特异性抗原急剧下降。

Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.

引用本文的文献

1

Down-regulation of androgen-receptor and PSA by phytochemicals.植物化学物质对雄激素受体和前列腺特异性抗原的下调作用。

Int J Oncol. 2008 Feb;32(2):405-11.